cambridge.org/cty

## **Images in Congenital Cardiac Disease**

Cite this article: Halperin LF, Krahn AD, and Laksman ZW (2021) Documenting the descent remote monitoring and adult-onset Catecholaminergic Polymorphic Ventricular Tachycardia associated with ventricular fibrillation and bradycardia. Cardiology in the Young 31: 1330-1332. doi: 10.1017/ S1047951121002377

Received: 11 February 2021 Revised: 1 April 2021 Accepted: 25 May 2021 First published online: 21 June 2021

#### **Keywords:**

Arrhythmia; electrophysiology; extended cardiac monitoring; inherited arrhythmia

#### Author for correspondence:

Dr. Zachary Laksman, Division of Cardiology, University of British Columbia, 211-1033 Davie Street, Vancouver, BC V6E 1M7, Canada. Tel: (604) 806-8256; Fax: (604) 806-8723. E-mail: zlaksman@mail.ubcca

# Documenting the descent – remote monitoring and adult-onset Catecholaminergic Polymorphic Ventricular Tachycardia associated with ventricular fibrillation and bradycardia

CrossMark

## Laura F. Halperin , Andrew D. Krahn and Zachary W. Laksman

Division of Cardiology, University of British Columbia, Vancouver, BC, Canada

### Abstract

This image highlights a 38-year-old female with ventricular fibrillation and spontaneous return to sinus rhythm found on an implantable loop recorder inserted for recurrent syncope. Ultimately, she was diagnosed with catecholaminergic polymorphic ventricular tachycardia, a rare inherited arrhythmia disorder.

A 38-year-old cardiac nurse who presented to multiple cardiologists with more than 15 episodes of exercise-induced syncope received a diagnosis of vasovagal syncope because of documented bradycardia in the early recovery phase. During exercise stress-testing, frequent ventricular ectopy was observed, and a Holter monitor captured rare bidirectional pre-mature ventricular contractions at increased heart rate, highly suggestive of catecholaminergic polymorphic ventricular tachycardia. As a result, beta-blockade was initiated (bisoprolol 2.5 mg daily) as the patient was concerned about potential side effects of non-selective beta-blockers, and an implantable loop recorder was inserted to confirm the diagnosis and to provide an early alert system. The patient was advised to avoid adrenaline surging sports but was non-compliant. While bouldering, she had a sudden collapse and ventricular fibrillation with spontaneous conversion to sinus bradycardia (Fig 1). After this event, the patient received an implantable cardioverter defibrillator after a discussion regarding alternative options, risks, and benefits. After her syncopal event, she was started on maximally tolerated nadolol (40 mg twice daily), and flecainide (50 mg twice daily) was started shortly thereafter for persistent ventricular ectopy seen on a repeated exercise stress test (Fig 2). This effectively suppressed ventricular ectopy on repeat treadmill testing. She has not had any further syncopal events on this combination of medical therapy."

Catecholaminergic polymorphic ventricular tachycardia is a rare inherited arrhythmia disorder characterised by the onset of polymorphic ventricular tachycardia (VT) in the setting of high adrenergic tone. Most often patients are diagnosed in young adolescence with exerciseinduced syncope, while patients presenting after the age of 21 years are typically female, gene negative, and less likely to experience life-threatening arrhythmias.

Current guidelines recommend beta-blocker therapy first line for catecholaminergic polymorphic ventricular tachycardia. Combination medical therapy (non-selective beta-blocker and flecainide), sympathectomy, and/or implantable cardioverter defibrillator insertion is recommended for those with recurrent sustained VT or syncope.<sup>1</sup> Combination medical therapy may be considered by some for initial therapy in high-risk patients. Implantable cardioverter defibrillator insertion must be carefully considered in patients with catecholaminergic polymorphic ventricular tachycardia who are at risk of implantable cardioverter defibrillator discharges precipitating adrenergically mediated storm and should be a part of comprehensive care that includes maximally tolerated medical therapy and/or sympathectomy.<sup>2,3</sup> In this case, it was felt that the patient was high risk for further malignant arrhythmias given her recurrent syncope and

© The Author(s), 2021. Published by Cambridge University Press.






Figure 1. Image captured from implantable loop recording during loss of consciousness. Images demonstrates the presence of ventricular fibrillation and subsequent return to sinus bradycardia.



Figure 2. This electrocardiogram (ECG) is from the patient's exercise stress test prior to initiation of flecainide while on nadolol 40 mg twice daily. This is depicted at Stage 5 of the Bruce Protocol after 13:00 minutes at 5.0 miles per hour at 18.0% incline. This ECG demonstrates significant ventricular ectopy at maximum exercise.

ventricular fibrillation despite being on beta-blocker therapy. Therefore, shared decision-making resulted in a decision for implantable cardioverter defibrillator implantation.

#### Acknowledgements. None.

**Financial support.** ZL received support from the Cardiology Academic Practice Plan at the University of British Columbia.

Conflicts of interest. None.

## References

1. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018; 72: e91–e220.

- Roston TM, Jones K, Hawkins NM, et al. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: a systematic review. Heart Rhythm 2018; 15: 1791–1799. doi: 10.1016/j.hrthm. 2018.06.046. Epub 2018 Jul 3. PMID: 30063211.
- Miyake CY, Webster G, Czosek RJ, et al. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate. Circ Arrhythm Electrophysiol 2013; 6: 579–587. doi: 10.1161/CIRCEP.113.000170. Epub 2013 May 11. PMID: 23667268.